NCT05913089 - A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

TQB2450 injection + Chemotherapy

"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Chemotherapy is a systematic treatment that kill fast growing cells."

DRUG

TQB2450 injection + Anlotinib Hydrochloride Capsule

"TQB2450 injection is a humanized monoclonal antibody targeting programmed death ligand -1 (PD-L1).~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."

Trial Locations (10)

100021

RECRUITING

Cancer Hospital of Chinese Academy of Medical Sciences, Beijing

100027

RECRUITING

Beijing Chaoyang Hospital, Capital Medical University, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

101149

NOT_YET_RECRUITING

Beijing Chest Hospital, Capital Medical University, Beijing

200030

NOT_YET_RECRUITING

Shanghai Chest Hospital, Shanghai

261044

RECRUITING

Weifang People's Hospital, Weifang

300070

NOT_YET_RECRUITING

Tianjin Medical University General Hospital, Tianjin

300222

RECRUITING

Tianjin Chest Hospital, Tianjin

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

030013

RECRUITING

Shanxi Cancer Hospital, Taiyuan